Security
Cognition Therapeutics, Inc. Common Stock · CGTX
CGTXNASDAQCommon stockCurrentCIK 1455365Updated Oct 23, 2026
Name history
COGNITION THERAPUTICS INC · through Dec 28, 2010
CGTX price & chart
Loading TradingView…
NASDAQ:CGTX on TradingView ↗About the company
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly $200 million in National Institutes of Health and related foundation grants, Cognition Therapeutics continues to advance clinical research in its efforts to bring forth solutions that meet patients where they are and reduce caregiver burden. Learn more at cogrx.com.
In the news
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update ↗
Recent filings
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
4 filing
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 43,395,000Source | 27,579,000Source | 38,896,000Source | 19,622,000Source | 34,369,000Source | 36,140,000Source | 23,500,000Source | 38,851,000Source | 48,390,000Source | 30,234,000Source | 35,163,000Source | 50,425,000Source |
| Property, Plant and Equipment, NetUSD | 159,000Source | 207,000Source | 87,000Source | 174,000Source | 234,000Source | 77,000Source | 190,000Source | 257,000Source | 93,000Source | 181,000Source | 284,000Source | 233,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 39,334,000Source | 22,011,000Source | 34,012,000Source | 10,743,000Source | 28,533,000Source | 31,130,000Source | 16,428,000Source | 34,671,000Source | 36,810,000Source | 25,009,000Source | 29,922,000Source | 41,562,000Source |
| Assets, CurrentUSD | 42,883,000Source | 26,830,000Source | 38,299,000Source | 19,049,000Source | 33,550,000Source | 35,814,000Source | 22,866,000Source | 37,968,000Source | 47,991,000Source | 29,555,000Source | 34,222,000Source | 47,647,000Source |
| Operating Lease, Right-of-Use AssetUSD | 353,000Source | 542,000Source | 510,000Source | 399,000Source | 585,000Source | 249,000Source | 444,000Source | 626,000Source | 306,000Source | 498,000Source | 657,000Source | 813,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 6,866,000Source | 13,097,000Source | 5,872,000Source | 12,593,000Source | 11,360,000Source | 6,229,000Source | 11,230,000Source | 9,991,000Source | 14,119,000Source | 11,484,000Source | 10,689,000Source | 10,176,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 88,000Source | 41,000Source | 95,000Source | 65,000Source | 40,000Source | 90,000Source | 62,000Source | 40,000Source | 90,000Source | 60,000Source | 32,000Source | 29,000Source |
| Additional Paid in CapitalUSD | 231,745,000Source | 181,759,000Source | 240,078,000Source | 197,338,000Source | 180,350,000Source | 233,038,000Source | 195,848,000Source | 179,160,000Source | 232,828,000Source | 193,850,000Source | 165,826,000Source | 155,820,000Source |
| Retained Earnings (Accumulated Deficit)USD | -195,304,000Source | -167,318,000Source | -207,149,000Source | -190,374,000Source | -157,381,000Source | -203,217,000Source | -183,640,000Source | -150,340,000Source | -198,647,000Source | -175,160,000Source | -141,189,000Source | -115,401,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | -195,000Source | -199,000Source |
| Stockholders' Equity Attributable to ParentUSD | 36,529,000Source | 14,482,000Source | 33,024,000Source | 7,029,000Source | 23,009,000Source | 29,911,000Source | 12,270,000Source | 28,860,000Source | 34,271,000Source | 18,750,000Source | 24,474,000Source | 40,249,000Source |
| Liabilities and EquityUSD | 43,395,000Source | 27,579,000Source | 38,896,000Source | 19,622,000Source | 34,369,000Source | 36,140,000Source | 23,500,000Source | 38,851,000Source | 48,390,000Source | 30,234,000Source | 35,163,000Source | 50,425,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,654,000Source | 12,705,000Source | 5,450,000Source | 12,364,000Source | 10,920,000Source | 6,053,000Source | 10,950,000Source | 9,503,000Source | 13,924,000Source | 11,142,000Source | 10,169,000Source | 7,795,000Source |
| Operating Lease, Liability, CurrentUSD | 168,000Source | 188,000Source | 89,000Source | 198,000Source | 184,000Source | 95,000Source | 194,000Source | 180,000Source | 136,000Source | 193,000Source | 174,000Source | 149,000Source |
| Accounts Payable, CurrentUSD | 827,000Source | 1,895,000Source | 673,000Source | 771,000Source | 3,034,000Source | 3,850,000Source | 1,821,000Source | 2,639,000Source | 1,119,000Source | 1,984,000Source | 3,695,000Source | 3,216,000Source |
| Operating Lease, Liability, NoncurrentUSD | 212,000Source | 392,000Source | 422,000Source | 229,000Source | 440,000Source | 176,000Source | 280,000Source | 488,000Source | 195,000Source | 342,000Source | 520,000Source | 695,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 67,000Source | 110,000Source | 147,000Source | 178,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | 0Source | 1,686,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,923,000Source | 9,505,000Source | 3,833,000Source | 9,372,000Source | 6,064,000Source | 1,694,000Source | 7,708,000Source | 4,734,000Source | 11,995,000Source | 7,620,000Source | 4,055,000Source | 2,094,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 36,000Source | 107,000Source | 96,000Source | 83,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 330,000Source | 586,000Source | 2,087,000Source | 3,748,000Source | 4,354,000Source | 3,572,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | — | — | — | -1,092,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,542,000Source | -9,877,000Source | -24,588,000Source | -28,474,000Source | -16,018,000Source | -18,533,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 9,000Source | -4,000Source | -147,000Source | -171,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 4,000Source | 147,000Source | 171,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 164,000Source | 46,000Source | 164,000Source | 128,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -233,000Source | 1,296,000Source | 36,570,000Source | 23,565,000Source | 4,521,000Source | 5,546,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,775,000Source | -8,581,000Source | 11,991,000Source | -4,913,000Source | -11,640,000Source | -13,159,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 39,823,000Source | 22,011,000Source | 34,762,000Source | 11,557,000Source | 31,225,000Source | 16,428,000Source | 37,000,000Source | 25,009,000Source | 29,922,000Source | 41,562,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | — | 4,000Source | -1,000Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 2,000Source | 2,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 522,000Source | 896,000Source | 319,000Source | 621,000Source | 330,000Source | 586,000Source | 2,087,000Source | 3,748,000Source | 4,354,000Source | 3,572,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | — | 83,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | -5,000Source | — | -41,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 2,602,000Source | 3,071,000Source | 2,641,000Source | 2,497,000Source | 2,697,000Source | 2,989,000Source | 10,612,000Source | 12,290,000Source | 13,528,000Source | 13,227,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,930,000Source | -9,937,000Source | -3,932,000Source | -6,734,000Source | -4,570,000Source | -8,480,000Source | -23,487,000Source | -33,971,000Source | -25,788,000Source | -21,397,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -21,397,000Source |
| Operating ExpensesUSD | — | — | 6,375,000Source | 14,463,000Source | 7,738,000Source | 13,978,000Source | 8,817,000Source | 13,775,000Source | 47,799,000Source | 53,966,000Source | 50,724,000Source | 43,551,000Source |
| Operating Lease, ExpenseUSD | — | — | 54,000Source | 55,000Source | 53,000Source | 54,000Source | 47,000Source | 54,000Source | 215,000Source | 218,000Source | 215,000Source | 203,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,445,000Source | 4,526,000Source | 3,806,000Source | 7,244,000Source | 4,247,000Source | 5,295,000Source | 24,312,000Source | 19,995,000Source | 24,936,000Source | 22,154,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 44,000Source | — | 71,000Source | 82,000Source | — | 1,618,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -6,375,000Source | -14,463,000Source | -7,738,000Source | -13,978,000Source | -8,817,000Source | -13,775,000Source | -47,799,000Source | -53,966,000Source | -50,724,000Source | -43,551,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,445,000Source | 4,526,000Source | 3,806,000Source | 7,244,000Source | 4,247,000Source | 5,295,000Source | 24,312,000Source | 19,995,000Source | 24,936,000Source | 22,154,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,930,000Source | -9,937,000Source | -3,932,000Source | -6,734,000Source | -4,570,000Source | -8,480,000Source | -23,487,000Source | -33,971,000Source | -25,788,000Source | -21,397,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.06Source | -0.25Source | -0.04Source | -0.11Source | -0.05Source | -0.14Source | -0.32Source | -0.86Source | -0.86Source | -0.91Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.06Source | -0.25Source | -0.04Source | -0.11Source | -0.05Source | -0.14Source | -0.32Source | -0.86Source | -0.86Source | -0.91Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 77,951,513Source | 40,418,065Source | 90,624,381Source | 63,690,945Source | 89,191,313Source | 61,828,149Source | 72,766,983Source | 39,730,148Source | 30,029,087Source | 23,640,199Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 77,951,513Source | 40,418,065Source | 90,624,381Source | 63,690,945Source | 89,191,313Source | 61,828,149Source | 72,766,983Source | 39,730,148Source | 30,029,087Source | 23,640,199Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 2,602,000Source | 3,071,000Source | 2,641,000Source | 2,497,000Source | 2,697,000Source | 2,989,000Source | 10,612,000Source | 12,290,000Source | 13,528,000Source | 13,227,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 23,487,000Source | -33,971,000Source | -25,767,000Source | -21,384,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | -27,000Source | -28,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | -3,000Source | -3,000Source | -3,000Source | -5,000Source | -5,000Source | -13,000Source | -25,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -21,397,000Source |
| Operating ExpensesUSD | — | — | 6,375,000Source | 14,463,000Source | 7,738,000Source | 13,978,000Source | 8,817,000Source | 13,775,000Source | 47,799,000Source | 53,966,000Source | 50,724,000Source | 43,551,000Source |
| Operating Lease, ExpenseUSD | — | — | 54,000Source | 55,000Source | 53,000Source | 54,000Source | 47,000Source | 54,000Source | 215,000Source | 218,000Source | 215,000Source | 203,000Source |
| Research and Development ExpenseUSD | — | — | 3,773,000Source | 11,392,000Source | 5,097,000Source | 11,481,000Source | 6,120,000Source | 10,786,000Source | 37,187,000Source | 41,676,000Source | 37,196,000Source | 30,324,000Source |
Filing attachments
tm2628101d1_ex99-1.htm · 8-K · 2026-10-22
Exhibit 99.1 Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies PURCHASE, NY - October 22, 2026 - Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient sele…
Read attachment ↗tm2622462d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622462d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update Purchase, NY - August 6, 2026 - Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “The second quar…
Read attachment ↗tm2618699d1_ex99-1.htm · 8-K · 2026-06-24
EX-99.1 2 tm2618699d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, NY - June 24, 2026 - Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stag…
Read attachment ↗tm2616896d1_ex99-1.htm · 8-K · 2026-06-04
EX-99.1 2 tm2616896d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 https://cogrx.com COGNITION THERAPEUTICS · NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 · Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis 2 COGNITION THERAPEUTICS | NASDAQ: CGTX FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contain…
Read attachment ↗tm2615260d1_ex99-1.htm · 8-K · 2026-05-21
EX-99.1 2 tm2615260d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis - Positive Discussion on Path Forward for Registrational Program - PURCHASE, NY - May 21, 2026 - Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a plann…
Read attachment ↗tm2613845d1_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 tm2613845d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis Purchase, NY - May 7, 2026 - Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cogniti…
Read attachment ↗